The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).

被引：9
作者：
Jonker, Derek J.
Nott, Louise M.
Yoshino, Takayuki
Li, Chiang
Gill, Shariene
Shapiro, Jeremy David
Ohtsu, Atsushl
Zalcberg, John Raymond
Vickers, Michael M.
Slims, John
Wei, Alice Chia-Chi
Mittmann, Nicole
Magoski, Nadine M.
Murray, Yvonne
Tsobanis, Eric
Tu, Dongsheng
Kerstein, David
O'Callaghan, Christopher J.
机构：
[1] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[2] Royal Hobart Hosp, Hobart, Tas, Australia
[3] Natl Canc Ctr Hosp East, Chiba, Japan
[4] Boston Biomed Inc, Cambridge, MA USA
[5] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[6] Cabrini Hosp, Melbourne, Vic, Australia
[7] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan
[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[9] Tom Baker Canc Clin, Calgary, AB, Canada
[10] NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[11] Toronto Gen Hosp, Toronto, ON, Canada
[12] Sunnybrook Hlth Sci Ctr, HOPE Res Ctr, Toronto, ON M4N 3M5, Canada
[13] NCIC Clin Trials Grp, Kingston, ON, Canada
[14] NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps3660
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3660
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The BRIGHTER trial: A phase III randomized double-blind study of BBI-608+weekly paclitaxel versus placebo (PBC)) plus weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.
    Shah, Manish A.
    Muro, Kei
    Shitara, Kohei
    Tebbutt, Niall C.
    Bang, Yung-Jue
    Lordick, Florian
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
    Kang, Y. -K.
    Yau, T.
    Park, J. -W.
    Lim, H. Y.
    Lee, T. -Y.
    Obi, S.
    Chan, S. L.
    Qin, S. K.
    Kim, R. D.
    Casey, M.
    Chen, C.
    Bhattacharyya, H.
    Williams, J. A.
    Valota, O.
    Chakrabarti, D.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2015, 26 (12) : 2457 - 2463
  • [43] A multicenter, randomized, double-blind, phase III study of ramucirumab (IMC-1121B; RAM) and best supportive care (BSC) versus placebo (PBO) and BSC as second-line treatment in patients (pts) with hepatocellular carcinoma (HCC) following first-line therapy with sorafenib (SOR)
    Zhu, Andrew X.
    Chau, Ian
    Blanc, Jean-Frederic
    Okusaka, Takuji
    Rojas, Maria
    Yang, Ling
    Von Broen, Ingo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS)
    Le Cesne, A.
    Blay, J-Y.
    Cupissol, D.
    Italiano, A.
    Delcambre, C.
    Penel, N.
    Isambert, N.
    Chevreau, C.
    Bompas, E.
    Bertucci, F.
    Chaigneau, L.
    Piperno-Neumann, S.
    Salas, S.
    Rios, M.
    Guillemet, C.
    Bay, J-O.
    Ray-Coquard, L.
    Mir, O.
    Haddag, L.
    Foulon, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Randomized phase 3 study of maintenance therapy with S-1 plus best supportive care (BSC) versus BSC alone after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell lung carcinoma (WJOG7512L).
    Tanaka, Kaoru
    Morita, Satoshi
    Ando, Masahiko
    Yokoyama, Takuma
    Nakamura, Atsushi
    Yoshioka, Hiroshige
    Ishiguro, Takashi
    Miura, Satoru
    Toyozawa, Ryo
    Oguri, Tetsuya
    Daga, Haruko
    Ko, Ryo
    Bessho, Akihiro
    Tachihara, Motoko
    Iwamoto, Yasuo
    Hirano, Katsuya
    Nakanishi, Yoichi
    Nakagawa, Kazuhiko
    Yamamoto, Nobuyuki
    Okamoto, Isamu
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.
    Shapiro, J. D.
    Siu, L. L.
    Zalcberg, J. R.
    Moore, M. J.
    Ringash, J.
    Mittmann, N.
    Simes, J.
    O'Callaghan, C. J.
    Tu, D.
    Walters, I. B.
    Magoski, N.
    Smith, P.
    Nomikos, D.
    Zhu, L.
    Savoie, M.
    Virk, S.
    El-Tahche, F.
    Gill, R.
    Price, T. J.
    Jonker, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group
    Pelzer, Uwe
    Schwaner, Ingo
    Stieler, Jens
    Adler, Mathias
    Seraphin, Joerg
    Doerken, Bernd
    Riess, Hanna
    Oettle, Helmut
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (11) : 1676 - 1681
  • [48] A phase 2, randomized, double-blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low- or intermediate-1-risk myelodysplastic syndrome
    Garcia-Manero, Guillermo
    Gartenberg, Gary
    Steensma, David P.
    Schipperus, Martin R.
    Breems, Dimitri A.
    de Paz, Raquel
    Valcarcel, David
    Kranenburg, Britte
    Reddy, Manjula
    Komrokji, Rami S.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (09) : E156 - E162
  • [49] Phase III Randomized, Placebo-Controlled Study of Cetuximab Plus Brivanib Alaninate Versus Cetuximab Plus Placebo in Patients With Metastatic, Chemotherapy-Refractory, Wild-Type K-RAS Colorectal Carcinoma: The NCIC Clinical Trials Group and AGITG CO.20 Trial
    Siu, Lillian L.
    Shapiro, Jeremy D.
    Jonker, Derek J.
    Karapetis, Chris S.
    Zalcberg, John R.
    Simes, John
    Couture, Felix
    Moore, Malcolm J.
    Price, Timothy J.
    Siddiqui, Jehan
    Nott, Louise M.
    Charpentier, Danielle
    Liauw, Winston
    Sawyer, Michael B.
    Jefford, Michael
    Magoski, Nadine M.
    Haydon, Andrew
    Walters, Ian
    Ringash, Jolie
    Tu, Dongsheng
    O'Callaghan, Chris J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (19) : 2477 - 2484
  • [50] Phase IIb randomized trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), a targeted oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE)
    Heo, Jeong
    Chao, Yee
    Jonker, Derek J.
    Baron, Ari David
    Habersetzer, Francois
    Burke, James
    Breitbach, Caroline
    Patt, Richard H.
    Lencioni, Riccardo
    Homerin, Michel
    Limacher, Jean-Marc
    Lusky, Monika
    Hickman, Theresa
    Longpre, Lara
    Kirn, David H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345